Conventional cervical smears disclose histoplasmosis: a case report
DOI:
https://doi.org/10.18203/2320-6012.ijrms20251007Keywords:
Histoplasma capsulatum, Fungal infection, PAP smear, Vaginal discharge, Cytology, Systemic disease screeningAbstract
Histoplasmosis is an uncommon fungal infection caused by Histoplasma capsulatum, often presenting as a pulmonary disease in endemic regions. Extrapulmonary manifestations, particularly involving the genitourinary tract, are exceedingly rare and pose diagnostic challenges. This case report discusses a 36-year-old female who presented with a one-year history of foul-smelling white vaginal discharge, abdominal discomfort, and lower back pain. Cytological analysis of a pap smear revealed extracellular yeast-like cells consistent with histoplasma capsulatum. The smear was classified as negative for intraepithelial lesion or malignancy (NILM). Routine blood tests and organ function tests were normal, and further investigations were recommended to exclude systemic histoplasmosis, including serological detection of anti-H and anti-M antibodies using histoplasmin. The rarity of this presentation emphasizes the importance of considering fungal infections in the differential diagnosis of chronic gynecological symptoms, particularly in regions where histoplasmosis is endemic. Pap smear cytology, a cost-effective and accessible diagnostic tool, was pivotal in identifying the pathogen. Differential diagnoses such as candidiasis and cryptococcosis were ruled out based on the characteristic morphological features of histoplasma capsulatum. Comprehensive management, including systemic screening and potential antifungal therapy, is essential to prevent disease progression. This case underscores the need for heightened clinical awareness and a multidisciplinary approach to diagnose and manage rare fungal infections in gynecological practice. Additionally, it highlights the diagnostic utility of cytological methods in identifying atypical pathogens beyond routine cervical cancer screening.
Metrics
References
Wheat J, Azar MM, Bahr NC, Spec A, Relich RF, Hage C. Histoplasmosis. Infect Dis Clin North Am. 2016;30(1):207-27. DOI: https://doi.org/10.1016/j.idc.2015.10.009
Kauffman CA. Histoplasmosis: A Clinical and Laboratory Update. Clin Microbiol Rev. 2007;20(1):115-32.
Subramanian S, Abraham OC. Disseminated histoplasmosis. J Assoc Physicians India. 2006;54:785-9.
Watts B, West M. Diagnosing histoplasmosis in the clinical laboratory. Clin Lab Med. 2021;41(3):475-86.
Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev. 2007;20(1):115-32. DOI: https://doi.org/10.1128/CMR.00027-06
Barros N, Wheat JL, Hage C. Pulmonary Histoplasmosis: A Clinical Update. J of Fungi. 2023; 9(2):236. DOI: https://doi.org/10.3390/jof9020236
Deepe GS. Histoplasma capsulatum. Microbiol Spectr. 2015;3(1):1-19.
Valdez AF, Miranda DZ, Guimarães AJ, Nimrichter L, Nosanchuk JD. Pathogenicity & virulence of Histoplasma capsulatum - A multifaceted organism adapted to intracellular environments. Virulence. 2022;13(1):1900-19. DOI: https://doi.org/10.1080/21505594.2022.2137987
Oliveira M, Oliveira D, Lisboa C, Boechat JL, Delgado L. Clinical manifestations of human exposure to fungi. J of Fungi. 2023;9(3):381. DOI: https://doi.org/10.3390/jof9030381
Wheat J, Hafner R, Korzun AH, Limjoco MT, Spencer P, Larsen RA, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med. 1995;98(4):336-42. DOI: https://doi.org/10.1016/S0002-9343(99)80311-8
Wheat LJ, Cloud G, Johnson PC, Connolly P, Goldman M, Le Monte A, et al. Clinical Trials Group; Mycoses Study Group of NIAID. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrob Agents Chemother. 2001;45(8):2354-7. DOI: https://doi.org/10.1128/AAC.45.8.2354-2357.2001